Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01557777 · ClinicalTrials.gov registry record · Phase 2
Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT01557777 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 17 participants.
The verdict
NCT01557777, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
Open-label extension study of navitoclax in subjects with chronic lymphocytic leukemia (CLL).
Interventions
- DRUG Navitoclax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2012-06 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01557777
The ClinicalTrials.gov registry entry for NCT01557777 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Navitoclax is the first listed.
NCT01557777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01557777 about?
NCT01557777 is a clinical study titled "Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)". Open-label extension study of navitoclax in subjects with chronic lymphocytic leukemia (CLL).
What is the current status of trial NCT01557777?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2012-06. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01557777?
The interventions under investigation include: Navitoclax (DRUG).
Who is sponsoring clinical trial NCT01557777?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.